AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01422616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BP management policies
Description: Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.~The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
Study NCT01075217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iopamidol
Description: Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
Study NCT01075217 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iodixanol
Description: Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
Study NCT03870607 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotics in combination with probiotics
Description: Administration of prebiotics in combination with probiotics before the start of Ch-RT
Study NCT00869323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m\^2 intravenously on Days 1,8, 15 and 22
Study NCT03304964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FP-025 (MMP-12 inhibitor)
Description: Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
Study NCT03326830 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Description: oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher\&Paykel, New-Zealand).
Study NCT03326830 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy
Description: Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
Study NCT02660619 — intervention group
Intervention type: OTHER
Intervention: Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)
Study NCT06288958 — intervention group
Intervention type: OTHER
Intervention: Quality of Life and social participation in Italian children with CP
Description: CP-QOL and PEM-CY questionnaires are fulfilled by families of children.
Study NCT02738996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 60 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
Study NCT02738996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks either every 30 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
Study NCT02738996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sedentary time breaks every 15 minutes
Description: Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
Study NCT02365493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-Lactam
Study NCT02985502 — intervention group
Intervention type: OTHER
Intervention: pancreatogenic diabetes
Description: pancreatogenic diabetes
Study NCT03022669 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Study NCT03022669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Website
Description: American Heart Association patient education website
Study NCT02982538 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Extended Training in Prolonged Exposure Therapy for PTSD
Description: Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
Study NCT02982538 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard Training in Prolonged Exposure Therapy for PTSD
Description: Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
Study NCT01277341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Nasal Spray 2% Twice a day
Description: nasal spray
Study NCT01277341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Nasal Spray 3% Twice a day
Description: nasal spray
Study NCT01277341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine Besilate Nasal Spray 4% Twice a day
Description: nasal spray
Study NCT01277341 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray
Description: nasal spray
Study NCT04429334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nangibotide
Description: nangibotide 1.0 mg/kg/h
Study NCT04429334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo
Study NCT03060759 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Light Therapy box
Description: The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.
Study NCT03060759 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Light Therapy box
Description: The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs.
Study NCT02556307 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: Peginterferon alfa-2a according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
Study NCT02556307 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: Ribavirin according to the standard practice in line with current summaries \\nof product characteristics (SPCs)/local labeling.
Study NCT04623021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesilate
Description: Administered intravenously as a continuous infusion
Study NCT04415684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)
Description: For the right/test eye, a defocused image is projected onto the peripheral retina while the subject views a distant, in-focus image
Study NCT04415684 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: No Active projection of defocused image in the peripheral visual field (eSpecs, Acucela Inc.)
Description: For the left/control eye, no image is projected onto the peripheral retina. The subject views a distant, in-focus image.
Study NCT03537157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin delayed release tablets
Description: Active intervention
Study NCT03537157 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator placebo
Study NCT02358967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: TRF (Tocotrienol-rich-fraction)
Description: 2 x 150 mg capsules
Study NCT02358967 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 150 mg capsules
Study NCT01221246 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM602
Description: First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
Study NCT01221246 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
Study NCT03883282 — intervention group
Intervention type: OTHER
Intervention: Not Provided
Description: Not Provided
Study NCT02396173 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Risk Score for non-return to work
Description: The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice).
Study NCT01978899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immediate Weight Loss Program Group
Description: Participation in 15-week Healthy Living Program.
Study NCT01978899 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed Weight Loss Program Group
Description: Participation in 15-week Healthy Living Program following 15-week wait period.
Study NCT03261882 — intervention group
Intervention type: OTHER
Intervention: Nativity
Description: Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
Study NCT03720574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10 mg BID
Description: Lorcaserin 10 mg tablet each morning and evening for a duration of 48 weeks
Study NCT03720574 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo BID
Description: Matching Placebo tablet each morning and evening for a duration of 48 weeks
Study NCT00998972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 600 mg intravenous before and 2 hours after cerebral arteriography
Study NCT03421366 — intervention group
Intervention type: DRUG
Intervention: Posaconazole
Description: A triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients
Study NCT01194973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eculizumab
Description: All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
Study NCT04471402 — intervention group
Intervention type: DRUG
Intervention: Precedex
Description: Intranasal Precedex 3mcg/kg
Study NCT02027870 — intervention group
Intervention type: DEVICE
Intervention: EXCEL-II biodegradable polymer sirolimus-eluting stent
Description: EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
Study NCT03658187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
Study NCT03658187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
Study NCT03658187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IP
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
Study NCT03658187 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: IP
Description: Beige-brown powder with speckles in clear enteric coated caplet with berry flavor liquid.
Study NCT01470196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
Study NCT01470196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
Study NCT01470196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
Study NCT03469817 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI
Description: Patients who are part of Arm 2 will undergo an MRI at their 1 year post-operative visit.
Study NCT04702763 — intervention group
Intervention type: OTHER
Intervention: Eye-Tracker®T2 + e-VOG
Description: * 1st step: eyes movements assessed with standard video-oculography device~* 2° step: eyes movements assessed with e-VOG digital application~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care
Study NCT04702763 — intervention group
Intervention type: OTHER
Intervention: e-VOG + Eye-Tracker®T2
Description: * 1st step: eyes movements assessed with e-VOG digital application~* 2° step: eyes movements assessed with standard video-oculography device~* Patient study duration is about 30 minutes, the day the patient performs their standard video-oculography examination in routine care
Study NCT03560687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucrosomial Iron
Description: CardioSideral 2 caps per day
Study NCT04079491 — intervention group
Intervention type: OTHER
Intervention: questionnaire survey
Description: A web-based questionnaire will be send by the trade union for dental hygienists
Study NCT03694808 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluad Vaccine
Description: single adjuvanted dose (AD) intramuscular injection
Study NCT04620161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 20mg
Description: 20mg, once daily, oral administration
Study NCT04620161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 40mg
Description: 40mg, once daily, oral administration
Study NCT00869323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 intravenous bolus days 1, 8, 15 and 22
Study NCT01573130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise program
Description: An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
Study NCT04778917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-Molecular-Weight Heparins Calcium Injection
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions
Study NCT04620161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pradigastat Tablets 20mg matching Placebo
Description: once daily, oral administration
Study NCT04620161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pradigastat Tablets 20mg matching Placebo
Description: once daily, oral administration
Study NCT04778917 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low-Molecular-Weight Heparins Calcium Injection
Description: We use different dose of low-molecular-weight heparins calcium injection to different interventions
Study NCT02841150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMBRUVICA (Treatment A)
Description: IMBRUVICA (reference treatment), 4\*140 milligram (mg), capsules.
Study NCT02841150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib (Treatment B)
Description: Ibrutinib (test treatment), 1\*560 mg, tablet.
Study NCT00364013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
Study NCT00364013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
Study NCT00364013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX regimen
Description: The FOLFOX regimen consisted of oxaliplatin 85 mg/m\^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m\^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m\^2 IV bolus followed by 600 mg/m\^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
Study NCT04122937 — intervention group
Intervention type: PROCEDURE
Intervention: Cytoreductive surgery
Description: Partial removal of peritoneal tissue involved by neoplastic invasion
Study NCT02576613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MPP-S
Description: > 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
Study NCT02576613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TAU
Description: standard medical treatment without structured psychotherapeutic intervention
Study NCT01591239 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-Based Intervention
Description: Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
Study NCT01591239 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Group
Description: Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
Study NCT00187941 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Mofetil
Description: Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
Study NCT02889237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium
Description: Immediate administration of daily calcium supplementation for 12 weeks
Study NCT02889237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium + low dose vitamin D
Description: Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
Study NCT02889237 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium + high dose vitamin D
Description: Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
Study NCT01895218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside 1000
Description: A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
Study NCT01895218 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical Care
Description: Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
Study NCT01069523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine Extended Release
Description: Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.